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A combinatorial, phage-display library of human Fab antibody fragments was generated from IgG heavy chain (HC) and
light chain (LC) genes cloned from the lymphocytes of a vaccinia virus (VACV)-immune donor. To ascertain the complexity of
the library, nucleotide sequences of the variable regions of the HC and LC genes were determined. Fourteen distinct HC and
18 distinct LC (7 k and 11 l) that formed a combinatorial library of 22 Fabs were identified. Immune-precipitation of
radiolabeled VACV revealed that at least six different VACV proteins were recognized by the antibodies. Plaque-reduction
neutralization demonstrated that six of the Fabs neutralized VACV in the presence of anti-human antibody. ELISA studies
indicated that 15 of the Fabs were cross-reactive with monkeypox virus.
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BINTRODUCTION
Vaccinia virus (VACV) was used in the past as an
ffective vaccine against smallpox. Because smallpox
as eradicated in natural settings as a result of a 10-year
lobal vaccination campaign with live VACV (Fenner et
l., 1988), the virus is now used primarily as a vector for
xpressing foreign genes and as a vaccine for laboratory
orkers. Concerns regarding the use of smallpox virus
or biological warfare or terrorism (Breman and Hender-
on, 1998), the controversy over the proposed destruc-
ion of laboratory strains of smallpox virus (Roizman et
l., 1994; Donohoe, 1996), and the reemergence of mon-
eypox as a major human disease in Africa (Ivker, 1997;
ukinda et al., 1997) have fueled renewed interest in
ACV as a vaccine and as a diagnostic tool for other
oxvirus infections.
Although VACV is a generally safe vaccine, dissemi-
ated, life-threatening infections occur infrequently, es-
ecially in individuals with impaired immunity (Keane et
l., 1983). Such infections can be treated by therapeutic
dministrations of human VACV immune globulin (VIG).
IG is clearly efficacious in treating disseminated VACV
nfections (Feery, 1976); however, the reason for its effi-
acy is not well defined. Neutralization assays are used
o measure potency of VIG, but there are no convincing
ata to indicate that the neutralizing antibodies are the
nly, or even the primary, therapeutic components in VIG.
IG is in short supply, largely due to the small available
mmune-serum donor population and to the high cost of
1 To whom reprint requests should be addressed. Fax: (301) 619-
t439. E-mail: Cschmalj@detrick.army.mil.
189reparing and safety testing a product derived from hu-
an donors. Human monoclonal antibodies (MAb) offer
n obvious alternative to VIG. If VACV-specific MAb
imic the therapeutic effects of VIG, they would serve as
stable source of well-characterized, high-quality im-
une globulin without the risks typically associated with
uman blood products.
VACV is structurally and antigenically complex, with a
enome of ;192 kb encoding .100 polypeptides (Moss,
990). Most of what is known about humoral immunity to
ACV comes from studies with mouse MAb (Rodriguez et
l., 1985; Demkowitz et al., 1992; Wolffe et al., 1995). To
ate, human MAb to VACV have not been reported.
ommon techniques used for making human MAb, e.g.,
usion of spleen cells with an immortal partner or trans-
ormation with Epstein–Barr virus (EBV), are labor inten-
ive and often result in cells lines that are unstable or
roduce low levels of antibody (Glassy 1993). To circum-
ent these problems, molecular techniques have been
eveloped to produce combinatorial libraries of human
ab fragments by bacterial expression of heavy chain
HC) and light chain (LC) antibody genes and display of
he fragments on the surface of filamentous bacterio-
hage. The antibody genes can be recovered from im-
une or non-immune donors by RT–PCR using human
ntibody-specific primers. The amplified genes are
loned into phagemid vectors such as pComb3 (Barbas
nd Lerner, 1991). Within this vector, both the HC and LC
enes follow a lac Z promoter and pel B leader se-
uence. The leader sequence dictates transport of the
xpression products to the bacterial periplasmic space.
ecause the HC gene is cloned in-frame with a portion ofhe M13 bacteriophage gene III, expression results in a
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190 SCHMALJOHN ET AL.usion protein of the HC and the carboxyl-terminal por-
ion of a minor coat protein. The gene III portion of the
usion protein tethers the HC to the inner membrane of
he bacterial host. For phage-display, bacteria harboring
he pComb3 constructs are infected with helper phage.
he phage acquires the gene III product and conse-
uently the Fabs when they pass through the inner mem-
rane of the bacteria. After selection of phage that dis-
lay appropriate Fabs, it is possible to remove the gene
II region from the phagemid constructs; thus expressed
C and LC gene products are both secreted into the
eriplasmic space of the bacteria. Lysates of such bac-
eria will generate soluble Fabs (Barbas and Lerner,
991).
Such phage-display methodology permits rapid con-
truction of large combinatorial antibody libraries and
as been used successfully to produce human MAb to a
umber of pathogens (e.g., Burton, 1991; Williamson et
l., 1993; Zebedee et al., 1992; Hoogenboom et al., 1998).
he studies reported here are intended to lead toward a
etter understanding of the feasibility of developing hu-
an MAb that might be used to replace VIG, and sec-
ndarily, to generate defined human antibodies for use in
oxvirus diagnosis.
RESULTS
ynamics of VACV-specific B cells in peripheral blood
fter a secondary vaccination
To optimize our chances of obtaining a combinatorial
ibrary of VACV-specific Fabs, we first examined the ki-
etics of the humoral immune response to VACV. Se-
uential bleeds were obtained from a donor who had
eceived a primary vaccination .10 years earlier, and a
ooster vaccination at the start of our study. An initial
ample was taken just before vaccination, and seven
FIG. 1. Circulating VACV-specific antibodies and B cells. A VACV-imm
accine. Circulating anti-VACV IgG was measured by ELISA at various
imiting dilutions were added to 96-well plates. The frequency of circu
ontaining cell clones.dditional samples were obtained at 3- to 4-day intervals ihereafter. A final sample was obtained 60 days after the
oost. Circulating VACV-specific IgG, as measured by
LISA, peaked 16 days after vaccination and remained
igh through Day 60 (Fig. 1A). To measure circulating B
ells secreting antibodies to VACV, we transformed lym-
hocytes with Epstein–Barr virus (EBV) and performed
LISA to detect VACV-reactive clones. Approximately 5 3
07 peripheral blood lymphocytes (PBL) were recovered
rom each sample of heparinized blood. Of these, ;107
ere transformed, and the remainder were frozen at
70°C for subsequent library construction. The number
f VACV-reactive cell clones increased during the 3
eeks after vaccination and peaked in samples obtained
t Day 20 (Fig. 1B). After Day 24, the frequency of VACV-
pecific circulating B cells decreased rapidly. By Day 60,
nly one well had ELISA-positive cells. Based on these
esults, we used samples from Days 16 to 24 to construct
he phage-display library. The neutralizing antibody titer
or samples collected during this time frame was 1:80.
lthough we did not measure neutralizing antibody lev-
ls in other samples, results of a previous study indi-
ated that development of neutralizing antibodies paral-
eled the antibody response detected by ELISA. In that
tudy, sera from 21 volunteers, who were given booster
accinations with the same vaccine that was used in our
tudy, were analyzed by ELISA and by plaque-reduction
eutralization tests (PRNT). In both assays, peak titers
ere observed 14 days after vaccination and remained
early constant through Day 42 after vaccination (A.
chmaljohn, unpublished information).
ibrary construction and enrichment for phage-
isplaying VACV-specific Fabs
To construct the HC and LC cDNA libraries, we per-
ormed RT–PCR using total cytoplasmic RNA of VACV-
unteer was boosted with the licesnsed New York Board of Health VACV
after infection. B cells were transformed with Epstein–Barr virus and
cells secreting antibodies to VACV was estimated by ELISA of wellsune vol
times
lating Bnfected cells (;49 mg) and primers specific for human
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191PHAGE-DISPLAY LIBRARY OF HUMAN Fab TO VACCINIA VIRUSC IgG1 (Fd region) or for k and l LC. The cDNA was
loned into the phagemid vector pComb3 (Barbas and
erner, 1991).
To enrich for phage-displaying VACV-specific Fabs,
acterial supernatants were panned three times on
ACV-coated microtiter plates. Because phagemids that
ave been packaged into virions are capable of infecting
ale Escherichia coli to form colonies on selective
lates, we used a colony hybridization assay to estimate
he proportion of VACV-specific phage (packaged phage-
id) at each panning step. For this assay, ;300 colonies,
rown in the presence of ampicillin, were lifted onto
itrocellulose filters, and the membrane-bound human
ab fragments were detected by sandwich hybridization.
ew positive colonies were observed before panning, 32
ositive colonies after the first panning, 156 positive
olonies after the second panning, and 288 positive
olonies after the third panning. Therefore after the third
anning, .95% of the colonies were hybridization posi-
ive (Fig. 2).
election of clones
One hundred colonies were randomly selected from
he hybridization-positive population for additional char-
cterization. Periplasmic extracts of each clone were
ssayed by ELISA both for the presence of human-spe-
ific antibodies as well as VACV-specific antibodies. All
00 preparations contained human Fabs as indicated by
LISA results obtained with wells coated with goat anti-
uman IgG (Fab-specific). Control wells, coated with
FIG. 2. Colony hybridization of bacteria infected with phage recovere
ecovered after each of three rounds of panning were streaked on amp
ilters were incubated with partially purified VACV, fixed with formaldehy
abeled goat anti-human IgG (Fc-specific) and an enzymatic substrate.
anning, .95% of the colonies were hybridization positive (B).oat anti-mouse IgG (Fab-specific), were negative (data pot shown). Of these, 98 periplasmic preparations were
lso positive when assayed by ELISA on plates coated
ith VACV-infected cell lysates (data not shown). Restric-
ion enzyme analysis of phagemid DNA revealed that 11
f the clones had not retained complete HC and LC DNA.
e were unable to maintain 21 other clones in culture;
herefore a final combinatorial library of 66 clones were
urther characterized.
omplexity of the library
To identify unique Fabs, we determined the nucleotide
equences of the variable regions of the HC and LC and
ompared their deduced amino acid sequences. Four-
een HC variable regions were identified, each of which
iffered by at least one predicted amino acid from all of
he others (Fig. 3A). HC5 and HC11 had differences only
n framework region 4, which probably would not influ-
nce antigen specificity. HC85 had several framework
ifferences, but only two CDR differences when com-
ared to HC5. Similarly, HC7 and HC52 had only one
onservative amino acid substitution (S vs T) in CDR2 but
ere otherwise identical (Fig. 3A). However, nine distinct
ineages were apparent on a phylogenetic tree con-
tructed from the HC variable region amino acid se-
uences (Fig. 4).
Eighteen unique LC, 7 k, and 11 l, were identified
Figs. 3B and 4). As with the HC, some of the LC had only
inor differences in their CDR (Fig. 3B). Nine clearly
nique lineages (4 k and 5 l) were apparent on a
panning on VACV-coated microtiter wells. Bacteria infected with phage
ontaining agar plates and colonies lifted onto nitrocellulose filters. The
incubated with VACV-specific MAb followed by alkaline phosphatase-
ositive colonies were observed before panning (A), but after the thirdd after
icillin-c
de, and
Few phylogenetic tree constructed from LC variable region
s
a
A
192 SCHMALJOHN ET AL.FIG. 3. Deduced amino acid sequences of the variable regions of unique HC (A) and LC (B). Nucleotide sequences were determined by automated
equence analysis using cycle sequencing and specific primers. Variable region framework (Fr) and complementarity determining regions (CDR) were
ssigned by comparison to previously published antibody sequences. Complete sequences available in GenBank under Accession Nos. AJ241344–
J241375.
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193PHAGE-DISPLAY LIBRARY OF HUMAN Fab TO VACCINIA VIRUSmino acid sequences (Fig. 4). Combinations of these
C and LC produced 22 human Fabs (Table 1).
mmune precipitation of VACV proteins
Each of the unique Fabs was used to immune-precip-
tate radiolabeled, intracellular VACV polypeptides. Six
FIG. 4. Amino acid sequence relationships of HC and LC variable re
rogram (http://www.clustalw.genome.ad.jp/). Trees were viewed by us
T
Characteristics o
ab Genotype No. of clones IPa (kDa)
1 5H/5L 3 95 k
2 11H/11L 1 95 k
3 85H/85L 13 95 k
4 60H/60L 9 95 k
5 85H/36L 1 95 k
6 52H/85L 1 95 k
7 7H/7L 1 95 k
8 60H/77L 1 None
9 7H/54L 1 None
10 52H/54L 2 35k
11 52H/52L 7 35 k
12 79H/52L 4 35 k
13 1H/1L 1 35 k
14 37H/37L 2 34 k
15 27H/27L 6 39 k
16 27H/3L 3 39 k
17 53H/53L 4 62 k
18 80H/7L 1 14 k
19 17H/21L 1 14 k
20 17H/4L 2 14 k
21 17H/17L 1 None
22 40H/40L 1 Nonea IP, immune-precipitation; b PRNT, plaque-reduction neutralization test; c VAistinct sizes of polypeptides were observed with appar-
nt Mr of ;95-, 62-, 39-, 35-, 34-, and 14-kDa (Table 1, Fig.
). We did not perform competition experiments with the
abs, so it is possible that more than one VACV protein
f the same apparent size was recognized by different
abs.
Trees were derived by using Clustal W multiple sequence alignment
eView program (http://taxonomy.zoology.gla.ac.uk/rod/rod.html).
n Fabs to VACV
PRNT50
b PRNT50 1 aFab
ELISA (OD405 1:2 diln)
VACVc MPXVd
2 2 1.006 1.041
2 2 1.138 1.037
2 2 0.922 0.924
2 1 0.327 0.516
2 2 0.947 0.703
2 2 0.265 0.587
2 2 0.244 0.526
2 2 0.204 0.656
2 2 0.213 0.414
2 2 0.250 0.300
1 1 0.168 0.501
2 2 0.163 0.393
1 1 0.161 0.413
1 1 1.154 0.043
2 1 0.422 0.134
2 1 0.403 0.406
2 2 0.147 0.015
2 2 0.249 0.329
2 2 0.202 0.033
2 2 0.049 0.000
2 2 0.149 0.007
2 2 0.092 0.008gions.ABLE 1
f HumaCV, vaccina virus; d MPXV, monkeypox virus.
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194 SCHMALJOHN ET AL.Within the library, Fabs reactive with the 95-kDa pro-
ein(s) were most common (29 Fabs, seven genotypes)
Table 1, Fig. 5). Of the remaining Fabs, the most com-
only recognized proteins had apparent sizes of 35-kDa
14 Fabs, four genotypes), 39-kDa (nine Fabs, two geno-
ypes), 14-kDa (four Fabs, three genotypes), 62-kDa (four
abs, one genotype), and 34-kDa (two Fabs one geno-
ype) (Table 1, Fig. 5). Four of the Fabs (8, 9, 21, and 22)
id not immune precipitate any detectable VACV
olypeptide.
laque-reduction neutralization tests (PRNT)
One goal of our study was to generate human neutral-
zing antibodies to VACV. To screen our library of Fabs for
eutralizing activity, we performed PRNT with 1:10 dilu-
ions of periplasmic bacterial extracts of each of the
abs. Three of the Fabs, 11, 13, and 14, reduced the
umber of VACV plaques by .50% (Table 1). Because the
abs were monovalent and neutralization might require
ivalent antibodies, and/or Fc regions, we repeated the
FIG. 5. Immune precipitation of radiolabeled VACV proteins. VACV
nfection of Vero E6 cells. Numbers above lanes correspond to those
ecognize each of six distinct VACV polypeptides are shown compared
G9) and to the VACV D8L polypeptide (mouse MAb 5B3). (B) Immune pr
longer exposure of the film, which was required to visualize imm
olypeptides of ;34-, 35-, 39-, and 62-kDa are shown compared to imm
B8 and 5B3), or the VACV L1R protein (MAb 10F5). (D) Immune precipRNT with the addition of goat anti-human IgG, Fab- epecific antibody. In this assay, three additional Fabs
lso neutralized VACV (Fab 4, 15, and 16, Table 1). Thus
abs reactive with the 34-, 35-, 39-, and 95-kDa proteins
ere neutralizing.
Of the neutralizing Fabs, Fabs 4 and 14 (reactive with
5- and 34-kDa proteins, respectively), appeared to neu-
ralize VACV most effectively. To more closely examine
heir neutralizing properties, we excised the gene III
usion protein portion of the plasmid constructs, tran-
ormed E. coli with the modified plasmids, and affinity-
urified the resultant soluble Fabs. We examined the
urified Fabs by gel electrophoresis and Coomassie
lue staining and estimated their quantities by compar-
ng them to bovine serum albumin (BSA) standards (Fig.
A). For a control, we prepared Fabs by papain digestion
f a mouse MAb, 10F5, which is known to neutralize
ACV and to recognize a 26-kDa protein encoded by the
ACV L1R ORF (Fig. 5C and unpublished information). We
lso cloned and expressed the Fab regions of the HC
nd LC antibody genes of the 10F5 hybridoma. The
s were radiolabeled with 35[S]methionine and cysteine 1–12 h after
le 1. (A) Immune precipitation with Fabs representative of those that
une precipitation with mouse MAb to the VACV hemagglutinin (MAb
ion with Fabs recognizing a 95-kDa polypeptide. The right panel shows
ecipitation by Fab 6. (C) Immune precipitation by Fabs recognizing
recipitation with mouse MAb recognizing the VACV D8L protein (MAb
by Fabs recognizing 14-kDa polypeptide(s).protein
in Tab
to imm
ecipitat
une pr
une pxpressed and papain-derived Fabs appeared as dou-
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195PHAGE-DISPLAY LIBRARY OF HUMAN Fab TO VACCINIA VIRUSlets of ;23- to 30-kDa on Coomassie blue-stained gels
Figs. 6A and 6B). Not all of the Fabs had identical
pparent Mr, most likely reflecting their different amino
cid sequences. A small amount of the uncleaved IgG
as seen in the papain-digested Fab preparation (arrow,
ig. 6B).
The complete IgG of the 10F5 mouse MAb neutralized
ACV (.50%) at all 10-fold dilutions $0.075 mg/ml (Fig.
A). In contrast, .50 mg/ml of the papain-digested IgG
as required to neutralize VACV (Fig. 7A). A 100-fold
ecrease in concentration (0.5 mg/ml) was required for
eutralization if the Fab was first incubated with anti-
ouse IgG Fab-specific antibody (Fig. 7A). Similarly, ex-
ressed 10F5 Fab in crude periplasmic bacterial extracts
id not neutralize VACV unless incubated in the pres-
nce of the anti-Fab antibody (Fig. 7A). Thus as we
etermined with the expressed human Fabs, a second-
ry antibody can increase the neutralizing activity of the
apain-derived mouse Fab. For the human expressed
abs 4 and 14, ;1 or 2 mg/ml, respectively, was required
o achieve .50% neutralization (Fig. 7B).
ross reactivity of the Fabs with monkeypox virus
To further characterize the library and to identify anti-
odies that might be useful for diagnosis of human
isease, we evaluated the reactivity of the Fabs with
nother pathogenic orthopoxvirus, monkeypox virus
MPXV), by ELISA. Most of the Fabs that reacted well in
LISA with VACV also reacted well with MPXV. Fab 14,
hich had the best neutralizing activity for VACV, ap-
FIG. 6. SDS–polyacrylamide gel electrophoresis of affinity-purified
abs or IgG. Numbers above lanes correspond to those in Table 1.
oomassie-blue-stained gels (A and B) showing affinity purified Fabs,
repared from periplasmic extracts of cells containing phagemids
ithout the gene III region. Approximately 1 mg of recovered samples
as compared to BSA standards. The mouse MAb 10F5, which recog-
izes the VACV L1 R protein, was purified by affinity chromatography
10F5 IgG) or was first digested with papain, and the Fab purified by
ffinity chromatography (10F5Fab). Arrow indicates the small amount of
gG that remained after papain digestion.eared to be specific for VACV (Table 1). (DISCUSSION
This study demonstrates the feasibility of using phage-
isplay techniques to produce human antibodies to
ACV. The 22 Fabs that we characterized reacted with at
east six different VACV proteins. At least four of those
roteins had neutralizing epitopes. Although it is likely
hat the Fabs recognized immunodominant epitopes on
ACV, the nature of the VACV antigen used to pan the
ecombinant phage surely influenced which Fabs were
btained. Our panning antigen consisted of partially pu-
ified VACV recovered from infected cells; consequently,
ntibodies reactive with proteins present on the intracel-
ular mature virus (IMV) rather than extracellular envel-
ped virus (EEV) were favored. Purification was not suf-
iciently extensive, however, to exclude VACV proteins
ot found in IMV. Therefore the library of Fabs that we
enerated represents an unknown subset of total anti-
odies to VACV produced by this donor. In addition, our
ab library may not represent the human immune re-
ponse to VACV in general, because it was derived from
single donor. In future studies, we intend to select
dditional antibodies reactive with antigens known to
licit protective immunity to VACV (such as L1R and D8L
ene products) by panning on lysates from cells trans-
ected with genes expressing defined VACV genes. We
lso have obtained PBL samples from several additional
accinated donors for use in expanding our Fab library.
Although we did not attempt to identify the VACV pro-
eins recognized by the Fabs, we compared their sizes to
hose precipitated by mouse MAb of known specificity by
el electrophoresis. The largest polypeptide recognized
y our library comigrated with VACV hemagglutinin (HA),
hich is recognized by mouse MAb, 4G9 (A. Schmaljohn,
npublished information) and is encoded in ORF A56R
Shida, 1986). Because HA is found in EEV and on mem-
ranes of infected cells, but not in IMV (Moss, 1990), it is
ossible that the protein recognized by the Fabs was not
A. Another VACV protein of this size is a major core
rotein, P4a, which has a predicted molecular mass of
02 kDa (Van Meir and Wittek, 1988) and an observed Mr
f 95 kDa (Vanslyke et al., 1991). However, this protein is
leaved to yield a 62-kDa mature core protein. (Demko-
icz and Ennis, 1993), which was not apparent in our
recipitation experiments. Conversely, one of our Fabs,
ab 17, did recognize a protein of ;62 kDa (but did not
ecognize a larger precursor).
Electrophoretic comparison of VACV proteins immune
recipitated with our Fabs or with mouse MAb 5B3 and
B8, which are specific for the D8L protein (A. Schmal-
ohn, unpublished information), demonstrated that Fab 14
ecognized a protein of the same size (34 kDa) and that
abs 10, 11, 12, and 13 recognized protein(s) that ap-
eared slightly larger (;35 kDa). A similar size protein36 kDa) was described previously to be immunodomi-
n
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196 SCHMALJOHN ET AL.ant in humans, but its specificity was not determined
Demkowicz et al., 1992).
We did not have defined mouse MAb available to
ompare with our Fabs that recognized either the 39- or
he 14-kDa polypeptide(s). One possible identity of the
arger polypeptide is the VACV protein encoded in the
4L ORF and which was also reported to be immuno-
ominant in humans (Maa and Esteban, 1987; Demko-
icz et al., 1992). Several VACV polypeptides of ;14 kDa
ave been described (Dallo et al., 1987; Rodriguez and
FIG. 7. Neutralization of VACV with affinity-purified antibodies or F
apain-derived Fab in the presence or absence of anti-Fab. Also compa
hagemids expressing the 10F5 Fab. Dilutions of 1:10 and 1:100 of the
ssayed. (B) Comparison of VACV-neutralization by papain-derived Fabsteban, 1987; Rodriguez et al., 1987, 1997; Salmons et tl., 1997). One of these is an immunodominant polypep-
ide encoded in ORF A27L (Demkowicz et al., 1992)
eported to be involved in fusion of the virus and cell
embrane (Rodriguez and Esteban, 1987).
Four of our Fabs did not immune precipitate any de-
ectable VACV polypeptide. Of these, Fabs 8 and 9 had
C variable regions that were identical to those of Fab 4
nd 7, respectively. Because both Fabs 4 and 7 reacted
ith the 95-kDa protein(s), Fabs 8 and 9 may also be
pecific for that protein. Likewise, because Fab 21 had
) Neutralization by the mouse MAb 10F5 was compared to that of
s neutralization achieved with periplasmic extracts of E. coli containing
smic extracts, in the presence or absence of anti-Fab antibodies were
Fab 14, and Fab 4 in the presence of anti-Fab antibodies.abs. (A
red wa
periplahe same HC as Fabs 19 and 20 (both of which react with
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197PHAGE-DISPLAY LIBRARY OF HUMAN Fab TO VACCINIA VIRUS14-kDa protein), we suspect that Fab 21 is also specific
or a 14-kDa protein. Clone 22 had unique HC and LC
ariable regions, thus we could not infer specificity for
hat antibody.
None of our Fabs was strongly neutralizing without
dded anti-Fab antibodies. Even then, only Fabs 4 and 14
eutralized VACV at dilutions .1:20. Whether or not the
eutralizing activity of these antibodies will be improved
nce they are engineered as complete IgG, remains to
e determined. If the re-engineered antibodies do dis-
lay good neutralizing activity, then we will be interested
n evaluating their protective and therapeutic properties
n animal models.
In addition to possible use in therapy, human antibod-
es to VACV may have application in diagnosis of other
athogenic poxviruses. For example, although MPxV
ases in humans were previously rare, an outbreak of
500 cases occurred recently in the Democratic Repub-
ic of Congo (CDC, 1998). We found that many of our Fabs
eacted equally well with VACV and MPxV in ELISA. We
ntend to further study potential of these Fabs for or-
hopox virus diagnosis.
MATERIALS AND METHODS
accination and lymphocyte preparation
A volunteer, who had been vaccinated with VACV .10
ears previously, was boosted with the licensed New
ork Board of Health VACV vaccine (Connaught Labora-
ories). Fifty-milliliter blood samples were withdrawn at
arious intervals after vaccination and peripheral blood
ymphocytes (PBL) were isolated by centrifugation, with
istopaque-1077 (Sigma).
BV transformation of lymphocytes and assay for
ACV-specific circulating B cells
Isolated PBL were infected with Epstein–Barr virus
EBV) and grown in 96-well U-bottom plates (Costar), at
100,000 cells/well, in Cyclosporin A-containing me-
ium (1 mg/ml in RPMI 1640/10% fetal bovine serum
FBS) (Melamed et al., 1985). When vigorous growth of
ransformed cells was observed in all wells (12–15 days
fter infection), supernatants from each well were as-
ayed for IgG-anti-VACV antibody by indirect ELISA. The
roportion of IgG-anti-VACV-producing B cells in circula-
ion was estimated by the number of ELISA-positive
ells/the number of the wells with cell growth after
BV-transformation.
NA preparation and library construction
Total cytoplasmic RNA was extracted from ;2 3 107
BL. RNA was converted to first-strand cDNA by using a
DNA synthesis kit (Boehringer Mannheim) and Oligo
dT) primers as directed by the manufacturer. PCR am-
lification of the IgG1 (Fd region) genes or the k and l LC tenes was performed by using combinations of 20 prim-
rs described in Table 2 of a previous study (Kang et al.,
991). Approximately equal amounts of PCR-amplified k
nd l chain cDNAs were pooled and cut with the restric-
ion enzymes XbaI and SacI, then ligated to the XbaI/SacI
inearized phagemid vector, pComb3 (Barbas and Lerner,
991; Barbas et al., 1991). E. coli XL1-Blue cells were
ransformed with the DNA by electroporation. Phagemid
NA was prepared, cut with XhoI and SpeI, and ligated
o XhoI/SpeI-digested, PCR-amplified IgG1(Fd) genes. To
enerate recombinant phage, E. coli transformed with
he pComb3 construct was infected with helper phage
VCS-M13) and the culture was incubated at 37°C over-
ight. Phage was precipitated from the supernatant of
he overnight culture, then resuspended in 2 ml of phos-
hate-buffered saline (PBS) and stored at 220°C as
escribed previously (Barbas and Lerner, 1991; Barbas et
l., 1991).
anning and colony hybridization assays
To enrich for phage-displaying VACV-specific Fabs on
heir surfaces, infected-cell supernatants were panned
y methods similar to those reported earlier (Barbas and
erner, 1991; Burton, 1991) but with VACV that was par-
ially purified as follows. Infected Vero E6 cells were
arvested by scraping with a rubber policeman and were
entrifuged for 5 min at 500 g. The cells were resus-
ended in 1 mM Tris–HCl (pH 8.8) and disrupted with
0–25 strokes of a Dounce homogenizer. Nuclei were
emoved by centrifugation and the supernatant was lay-
red onto a 35% sucrose cushion prepared in Tris–HCl,
H 8.8. After centrifugation in an SW27 rotor (Beckman)
t 18,000 rpm for 80 min, the pellet was resuspended in
mM Tris–HCl and layered onto a 34-ml 25–40% sucrose
radient. The samples were centrifuged at 13,500 rpm in
n SW27 rotor at 4°C for 40 min. The visible viral band
as collected with a Pasteur pipet and diluted threefold
n 1 mM Tris–HCl. The virus was concentrated by cen-
rifuging at 13,000 rpm in an SW27 rotor for 40 min. The
esultant pellets were resuspended in 1 mM Tris–HCl.
or panning, the partially purified virus was measured by
sing a BCA assay kit (BioRad) and diluted to 50 mg/ml
n carbonate-bicarbonate buffer, pH 9.6, and 100 ml was
dded to wells of 96-well microtiter plates.
Phage libraries (packaged phagemids) were assayed
y colony hybridization after each of three successive
annings to estimate the proportion of specific clones.
or the hybridization assays, bacterial clones from each
ound of panning were streaked on LB/ampicillin plates,
nd nitrocellulose filters were prepared and blocked as
escribed elsewhere (Barbas and Lerner, 1991; Barbas
t al., 1991). The filters were incubated with partially
urified VACV (20 mg/ml) in 1% BSA/PBS, fixed with 3.7%
ormaldehyde (w/v) in PBS (pH 7.2) for 30 min at room
emperature, then washed and incubated with ;50
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198 SCHMALJOHN ET AL.g/ml of a VACV-specific MAb secreted from a mouse-
uman hybridoma (Cui, unpublished data). The filters
ere next incubated with alkaline phosphatase-labeled
oat anti-human IgG (Fc-specific) (Sigma), which was
xtensively preadsorbed with E. coli XL1-Blue cell ly-
ates and then diluted 1:1000 with blocking buffer (3%
SA and 3% powdered milk in PBS). After three washes
n PBS/0.05% Tween 20, the filters were reacted with
CIP and NBT phosphatase substrates (Kirkegaard &
erry), which form colored precipitates (Harlow and
ane, 1988).
reparation of Fab fragments
After three rounds of panning, the packaged phage-
ids were used to infect fresh E. coli XL1-Blue cells
OD600 5 1.0). The phage and cells were incubated for 15
in at room temperature and then plated on LB/ampicil-
in plates. One hundred colonies were randomly se-
ected, and each clone was grown in 10 ml of super broth
30 g of tryptone, 20 g of yeast extract, and 10 g of MOPS
er liter, pH 7.0) containing 50 mg/ml of ampicillin, 10
mg/ml of tetracycline, and 20 mM MgCl2. Fab synthesis
as induced by adding isopropyl B-D-thiogalactopyrano-
ide (IPTG) to 1 mM, and the soluble Fab fragments were
repared as bacterial crude extracts as described pre-
iously (Barbas and Lerner, 1991; Barbas et al., 1991;
urton, 1991). These extracts were used for ELISA, im-
une precipitation, and PRNT or stored at 220°C.
For selected clones, the gene III portion of the plasmid
as excised by digesting pComb3 contructs with SpeI
nd NheI, purifying the linearized plasmid by agarose gel
lectrophoresis, recovering the fragment by binding to
lassmilk, and religating. The plasmids (without gene III)
ere then used to transform competent E. coli (dH5,
ibco-BRL) and 1-L cultures were prepared. The bacteria
ere lysed and Fabs purified from crude extracts by
ffinity-chromatography with goat anti-human IgG (Fab
pecific) (Sigma) immobilized on a Protein G matrix,
repared as described elsewhere (Harlow and Lane,
988). Fab fragments were eluted in 0.2 M glycine: HCl
pH 2.5) and immediately brought to neutral pH with 1 M
ris–HCl (pH 9.0).
reparation of papain-derived or expressed Fabs
rom a neutralizing, VACV-specific mouse MAb
Bacterially expressed recombinant Fab fragments
ere cloned from a mouse hybridoma, 10F5, which se-
retes a MAb that neutralizes VACV to high titer (A.
chmaljohn, unpublished information). Fabs were gener-
ted by the same methods as preparation of the human
abs to VACV described above except that the primers
or PCR-amplification of the antibody genes were spe-
ific for mouse IgG2a-k (Kang et al., 1991). 10F5 IgG
olecules were purified by affinity chromatography withhe MAb Trap G kit, (Pharmacia), and papain-digested oab fragments of 10F5 IgG molecules were prepared
ith the ImmunoPure Fab Preparation Kit (Pierce), ac-
ording to the manufacturer’s directions.
equence analysis of HC and LC genes
The nucleotide sequences of the variable regions of
he HC and LC antibody genes were determined by cycle
equencing and analysis on an Applied Biosystems au-
omated sequencer. Sequence primers for HC (VH) or LC
VL) were: VH 40–140 59-GGG CGC CAG GGG GAA GAC-
9; VH 40–159 59-CGC TGG ATT GTT ATT ACT CG-39; VL
0–158 59-CTA AAC TAG CTA GTC GCC AAG-39; VL 40–
56 59- TTG AAG CTC CTC AGA GGA G-39; VL 40–157
9-CCA GAT TTC AAC TGC TCA TC-39. An additional
rimer for k LC sequencing was: Ck 116–111 59-GAA
AC AGA TGG TGC AGC-39. Nucleotide sequences of
oth strands of every clone were determined. DNA and
educed amino acid sequences were analyzed by using
NA Strider and Clustal Software (http://www.clustalw.
enome.ad.jp/). Trees were viewed by using TreeView
oftware (http://taxonomy.zoology.gla.ac.uk/rod/rod.html).
nzyme-linked immunosorbent assay (ELISA)
Antigen preparation. The Connaught human vaccine
train of VACV, which originated from the New York City
oard of Health strain, was previously plaque purified
hree times on monolayers of MRC-5 human diploid lung
ells (ATCC CCL171) (Schmaljohn et al., 1990). Vero cells
ere cultured in minimal essential medium (MEM) with
arle’s salts, supplemented with 5% (cell propagation) or
% (virus growth and assay) FBS and with gentamicin (40
g/ml). VACV was grown in Vero cells and purified es-
entially as previously described (Schmaljohn et al.,
990). In brief, cells in roller bottles were infected at a
ultiplicity of infection of ,1. The cells were harvested
–4 days after infection when cytopathic effects had
ecimated the monolayers. Cells were centrifuged and
he pellet resuspended in 10 mM Tris–HCl (pH 8.0).
ysates were prepared by Dounce homogenization, and
larified by low-speed centrifugation.
For indirect ELISA, VACV-infected cell lysate, diluted in
arbonate-bicarbonate buffer (pH 9.6), was added to 96-
ell polystrene plates (50 ml/well) (Costar), and plates
ere incubated at 4°C overnight. An antigen dilution of
:100 was chosen empirically from prior titration. After 5%
owdered milk (w/v in PBS) was added to block nonspe-
ific binding, wells were rinsed and were ready to use.
ninfected Vero cell lysates at the same dilutions were
sed as antigen controls. The indirect ELISA was con-
ucted as previously described with alkaline phospha-
ase-conjugated goat anti-human or anti-mouse IgG (Fab
pecific) (Sigma) as the secondary antibody (Harlow and
ane, 1988).
For sandwich ELISA, affinity-purified goat anti-human
r anti-mouse IgG (Fab specific) (Sigma) was diluted to
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199PHAGE-DISPLAY LIBRARY OF HUMAN Fab TO VACCINIA VIRUS0 mg/ml in carbonate-bicarbonate buffer (pH 9.6) and
dded to the wells of plates (50 ml/well), and incubated
vernight at 4°C. The wells were washed three times
ith PBS/0.05% Tween 20 and then blocked by adding
00 ml of 5% powdered milk (w/v in PBS) and incubating
vernight at 4°C. The plates were then incubated with 50
l of human or mouse Fab-containing bacterial extracts
t 4°C overnight, washed three times with PBS/0.05%
ween 20, and 50 ml of diluted alkaline phosphatase
onjugated goat anti-human or anti-mouse antibody was
dded, and incubated for 1 h at 37°C. After five washes
ith PBS/0.05% Tween 20, 50 ml of p-nitrophenyl phos-
hatase substrate (Kirkegaard & Perry) was added and
olor development was monitored at 405 nm. Clones
ere scored as positive if OD405 readings were .0.3.
lkaline phosphatase-conjugated goat anti-human Fc or
nti-mouse Fc was used as an antibody control.
laque-reduction neutralization test (PRNT)
To assess plaque formation, virus was sonicated, al-
owed to adsorb to subconfluent monolayers of Vero
ells in six-well plates for 60 min at 37°C, and overlaid
ith MEM containing 2% FBS and 0.5% melted agarose.
hree to 4 days after infection, viable cells were stained
ith Neutral red and clear plaques visualized. VACV was
oncentrated and partially purified by pelleting homoge-
ized and sonicated VACV-infected cell lysates through
0% sucrose prepared in 10 mM Tris–HCl (pH 8.8) at
5,000 rpm for 2 h. VACV-containing pellets were resus-
ended in 10 mM Tris–HCl, sonicated, diluted to yield
200 plaque-forming units (pfu) per 0.1 ml, and mixed
ith an equal volume of antibody solutions at selected
ilutions. To assay neutralization by complete antibody
olecules, the VACV-antibody mixtures were incubated
t 4°C overnight before plating. For measuring neutral-
zation by human or mouse Fab fragments, VACV was
iluted to 250 pfu per 0.1 ml and mixed with 0.125 ml of
he Fab solutions at selected dilutions. After the VACV-
ab mixtures were incubated for 60 min at 37°C, 25 ml of
ffinity-purified goat anti-human or anti-mouse IgG (Fab
pecific) (Sigma) was added to the VACV-Fab mixture to
final concentration of 20 mg/ml. An equal volume (25 ml)
f PBS, pH 7.2 was used as a control. The VACV-Fab/
nti-Fab mixtures were incubated at 4°C overnight then
ssayed as above.
mmune precipitation
VACV-infected Vero E6 cells, in 75 cm2 flasks, were
adiolabeled from 1 to 6 h or from 6 to 12 h p.i. with 1 mCi
5S-Promix (Amersham) in 5 ml of methionine- and cys-
eine-deficient medium per flask. Cells were lysed with a
onionic detergent, Zwittergent 3–14 (Calbiochem), the
ysates pooled, and proteins were precipitated with im-
une sera essentially as previously described (Schmal-ohn et al., 1987), except that 50% protein G-agarose Meads coupled with the affinity-purified goat anti-human
gG-Fab (Sigma) were used to precipitate the VACV an-
igen-human Fab complexes. The Protein G/anti-human
gG-Fab beads were prepared as described previously
Harlow and Lane, 1988).
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